Supplemental bevacizumab may be useful in retinopathy of prematurity

Article

Intravitreal bevacizumab may be beneficial as a supplemental therapy for retinopathy of prematurity or as monotherapy in certain cases.

Intravitreal bevacizumab may be beneficial as a supplemental therapy for retinopathy of prematurity or as monotherapy in certain cases, according to data featured in Retina.

A team led by Dr Ruth Axer-Siegel, Department of Ophthalmology, Rabin Medical Center, Schneider Children's Medical Center of Israel, Petah Tiqwa, Israel, reviewed the files of nine consecutive infants who were administered intravitreal bevacizumab for the treatment of bilateral severe posterior retinopathy of prematurity. The gestational age was between 24 and 27 weeks and birth weight was between 660g to 1131 g.

Indications for treatment included retinopathy of prematurity progression from Stage 3 to 4A or 2 to 3 with extraretinal neovascularization, active neovascular Stage 4A disease after laser and cryo-treatment, anterior segment neovascularization and bleeding post-laser treatment and aggressive posterior disease with tunica vasculosa lentis and vitreous haze.

One patient underwent lens-spearing vitrectomy in 2 eyes after administration of bevacizumab. One eye developed macular fold and one patient underwent a bilateral scleral buckle. The anatomical results were favourable in 17 eyes and there were no reported local or systematic complications.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.